Active substance(s): DISODIUM HYDROGEN CITRATE / GLUCOSE / POTASSIUM CHLORIDE / SODIUM CHLORIDE
NAME OF THE MEDICINAL PRODUCT
QUALITATIVE AND QUANTITATIVE COMPOSITION
Sodium chloride 0.47g
Potassium chloride 0.30g
Disodium hydrogen citrate 0.53g
Powder for reconstitution with 200ml water.
For treatment of fluid and electrolyte loss associated with acute diarrhoea.
Posology and method of administration
Route of administration: Oral
The contents of each sachet should be dissolved in 200ml (approx. 7fl oz) of drinking water.
Use fresh drinking water for adults and children. For infants, and where drinking water is
unavailable, the water should be freshly boiled and cooled. The solution should be made up
immediately before use and may be stored for up 24 hours in a refrigerator, otherwise any
solution remaining an hour after reconstitution should be discarded. The solution itself must
not be boiled.
A basic principle of treatment of diarrhoea is to replace lost fluid and electrolytes and then to
maintain sufficient fluid intake to replace fluid loss from stools. The amount of reconstituted
Dioralyte administered should be adapted to the age and weight of the patient and the stage
and severity of the condition.
Severe dehydration may need to be corrected by parenteral fluids initially, followed by oral
maintenance if indicated. If the loss of fluid in the diarrhoea is excessive, medical advice
should be sought.
Daily intake may be based on a volume of 150ml/kg body weight for infants up to the age
of 2 and 20-40ml/kg body weight for adults and children.
A reasonable approximation is:
Infants up to the age of 2:
One to one and a half times the usual 24 hour feed volume.
One sachet dissolved in 200ml of water after every loose motion.
Adults (including the elderly):
One or two sachets after every loose motion. Each sachet should be dissolved in 200ml of
More may be required initially to ensure early and full volume repletion.
In the initial stages of treatment of diarrhoea all foods, including cow’s or artificial milk,
should be stopped. However breast milk need not be withheld. In breast fed infants it is
suggested that the infant is given the same volume of Dioralyte as the bottle fed baby and
then put to the breast until satisfied. Expression of residual milk from the breasts may be
necessary during this period. After 24-48 hours, when symptoms have subsided, the normal
diet should be resumed but this should be gradual to avoid exacerbation of the condition.
When vomiting is present with the diarrhoea it is advisable that small amounts of Dioralyte be
taken frequently. However, it is important that the whole of the required volume of Dioralyte
be taken. Where the kidneys are functioning normally, it is difficult to over-hydrate by mouth
and where there is doubt about the dosage, more rather than less should be taken. If no
improvement is seen within 24-48 hours it is recommended that the patient be seen by a
There are no known contraindications to Dioralyte. However, there may be a number of
conditions where treatment with Dioralyte will be inappropriate e.g. intestinal obstruction
requiring surgical intervention.
Special warnings and precautions for use
For oral administration only. Dioralyte should not be reconstituted in diluents other than
water. Each Sachet should always be dissolved in 200ml of water. A weaker solution than
recommended will not contain the optimal glucose and electrolyte concentration and a
stronger solution than recommended may give rise to electrolyte imbalance. If diarrhoea
persists unremittingly for longer than 24-48 hours the patient should be seen by a physician.
Dioralyte should not be used for the self treatment of chronic or persistent diarrhoea except
under medical supervision. Infants under the age of 2 years with diarrhoea should be seen by
a physician as soon as possible. No specific precautions are necessary in the elderly. Dioralyte
should not be used for self treatment by patients with liver or kidney disease, patients on low
potassium or sodium diets or patients with diabetes. The use of Dioralyte in patients with
these conditions should be supervised by a physician.
Interaction with other medicinal products and other forms of interaction
Pregnancy and lactation
Dioralyte is not contra-indicated in pregnancy or lactation.
Effects on ability to drive and use machines
Dioralyte could not be expected to affect the ability to drive or use machines.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the medicinal
product. Healthcare professionals are asked to report any suspected adverse reactions
via Yellow Card Scheme at: www.mhra.gov.uk/yellowcard
In the event of significant overdose, serum electrolytes should be evaluated as soon as
possible, appropriate steps taken to correct an abnormalities and levels monitored until return
to normal levels is established. This is particularly important in the very young and in cases of
severe hepatic of renal failure.
Dioralyte is an oral rehydration therapy. The combination of electrolytes stimulates water and
electrolyte absorption from the GI tract and therefore prevents or reverses dehydration in
Sodium and glucose are actively transported via the membrane into the enterocytes.
Sodium is then extruded into the intercellular spaces and the resulting osmotic gradient
causes water and electrolytes to be drawn from the gut and then into the circulation.
Preclinical safety data
No relevant data
List of excipients
Special precautions for storage
Store below 25°C. Store in the original package in order to protect from
Nature and contents of container
Foil/Laminate sachets containing powder for reconstitution with 200mL water.
Pack sizes 2, 4, 6 and 20 sachets.
Special precautions for disposal
The contents of each sachet should be dissolved in 200mL (approximately 7 fluid ounces) of
MARKETING AUTHORISATION HOLDER
Aventis Pharma Limited
One Onslow Street
or trading as:Sanofi-aventis or Sanofi
One Onslow Street
MARKETING AUTHORISATION NUMBER(S)
DATE OF FIRST AUTHORISATION/RENEWAL OF THE
DATE OF REVISION OF THE TEXT
Source: Medicines and Healthcare Products Regulatory Agency